T Cells Induce Pre-Metastatic Osteolytic Disease and Help Bone Metastases Establishment in a Mouse Model of Metastatic Breast Cancer

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Monteiro, Ana Carolina ^a,d   Leal, Ana Carolina ^a   Gonçalves Silva, Triciana ^a,d,e   Mercadante, Ana Carolina T ^a,d   Kestelman, Fabiola ^a   Chaves, Sacha Braun ^b   Azevedo, Ricardo Bentes ^b   Monteiro, João P ^c   Bonomo, Adriana ^a,d,e  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d INSTITUTO OSWALDO CRUZ   (Brazil)

^e FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17; OSTEOCLAST DIFFERENTIATION FACTOR; CYTOKINE; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MASS; BONE METASTASIS; BREAST METASTASIS; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MORPHOMETRICS; MOUSE; NEUROMODULATION; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; T LYMPHOCYTE; TUMOR ENGRAFTMENT; ANIMAL; BIOLOGICAL MODEL; BONE MARROW; BONE TUMOR; BREAST TUMOR; DISEASE MODEL; GENE INACTIVATION; GENETICS; IMMUNOLOGY; METABOLISM; OSTEOCLAST; PATHOLOGY; SECONDARY; T LYMPHOCYTE SUBPOPULATION; METASTASIS;

ANIMALS; ANTIGENS, NEOPLASM; BONE MARROW; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GENE KNOCKOUT TECHNIQUES; MICE; MODELS, BIOLOGICAL; OSTEOCLASTS; OSTEOLYSIS; RANK LIGAND; T-LYMPHOCYTE SUBSETS;

EID: 84880447117     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0068171     Document Type: Article

References (47)

1. Schreiber RD, Old LJ, Smyth MJ, (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331: 1565-1570. doi:10.1126/science.1203486. PubMed: 21436444.
2. Old LJ, Boyse EA, (1964) Immunology of experimental tumors. Annu Rev Med 15: 167-186. doi:10.1146/annurev.me.15.020164.001123. PubMed: 14139934.
3. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, et al. (2012) Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.Nature 482:400-404.
4. DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T, (2012) Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482: 405-409. doi:10.1038/nature10803. PubMed: 22318517.
5. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674. doi:10.1016/j.cell.2011.02.013. PubMed: 21376230.
6. Zitvogel L, Tesniere A, Kroemer G, (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6: 715-727. doi:10.1038/nri1936. PubMed: 16977338.
7. Bissell MJ, Hines WC, (2011) Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 17: 320-329. doi:10.1038/nm.2328. PubMed: 21383745.
8. Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, et al. (2010) Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A 107: 21677-21682. doi:10.1073/pnas.1016234107. PubMed: 21098274.
9. Peinado H, Alečković M, Lavotshkin S, Matei I, Costa-Silva B, et al. (2012) Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 18: 883-891. doi:10.1038/nm.2753. PubMed: 22635005.
10. Fidler IJ, (2003) The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3: 453-458. doi:10.1038/nrc1098. PubMed: 12778135.
11. Pardoll DM, (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12: 252-264. doi:10.1038/nrc3239. PubMed: 22437870.
12. Joyce JA, Pollard JW, (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9: 239-252. doi:10.1038/nrc2618. PubMed: 19279573.
13. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, et al. (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 1: 54-67. doi:10.1158/2159-8274.CD-10-0028. PubMed: 22039576.
14. DeNardo DG, Barreto JB, Andreu P, Vasquez L, Tawfik D, et al. (2009) CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 16: 91-102. doi:10.1016/j.ccr.2009.06.018. PubMed: 19647220.
15. Mundy GR, (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584-593. doi:10.1038/nrc867. PubMed: 12154351.
16. Roodman GD, (2004) Mechanisms of bone metastasis. N Engl J Med 350: 1655-1664. doi:10.1056/NEJMra030831. PubMed: 15084698.
17. Noonan K, Marchionni L, Anderson J, Pardoll D, Roodman GD, et al. (2010) A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 116: 3554-3563. doi:10.1182/blood-2010-05-283895. PubMed: 20664052.
18. Fournier PG, Chirgwin JM, Guise TA, (2006) New insights into the role of T cells in the vicious cycle of bone metastases. Curr Opin Rheumatol 18: 396-404. doi:10.1097/01.bor.0000231909.35043.da. PubMed: 16763461.
19. Monteiro JP, Benjamin A, Costa ES, Barcinski MA, Bonomo A, (2005) Normal hematopoiesis is maintained by activated bone marrow CD4+ T cells. Blood 105: 1484-1491. doi:10.1182/blood-2004-07-2856. PubMed: 15514013.
20. Fujisaki J, Wu J, Carlson AL, Silberstein L, Putheti P, et al. (2011) In vivo imaging of Treg cells providing immune privilege to the haematopoietic stem-cell niche. Nature 474: 216-219. doi:10.1038/nature10160. PubMed: 21654805.
21. Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, et al. (2011) Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 121: 1298-1312. doi:10.1172/JCI43414. PubMed: 21436587.
22. Di Rosa F F, (2009) T-lymphocyte interaction with stromal, bone and hematopoietic cells in the bone marrow. Immunol Cell Biol 87: 20-29. doi:10.1038/icb.2008.84. PubMed: 19030018.
23. Wong BR, Josien R, Choi Y, (1999) TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J Leukoc Biol 65: 715-724. PubMed: 10380891.
24. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, et al. (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402: 304-309. doi:10.1038/46303. PubMed: 10580503.
25. Takayanagi H, (2009) Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 5: 667-676. doi:10.1038/nrrheum.2009.217. PubMed: 19884898.
26. Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, et al. (2000) The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103: 41-50. doi:10.1016/S0092-8674(00)00103-3. PubMed: 11051546.
27. Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, et al. (1999) RANK is essential for osteoclast and lymph node development. Genes Dev 13: 2412-2424. doi:10.1101/gad.13.18.2412. PubMed: 10500098.
28. Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, et al. (2011) Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med 17: 1231-1234. doi:10.1038/nm.2452. PubMed: 21909105.
29. Xiong J, Onal M, Jilka RL, Weinstein RS, Manolagas SC, et al. (2011) Matrix-embedded cells control osteoclast formation. Nat Med 17: 1235-1241. doi:10.1038/nm.2448. PubMed: 21909103.
30. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, et al. (2006) Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 203: 2673-2682. doi:10.1084/jem.20061775. PubMed: 17088434.
31. Pöllinger B, Junt T, Metzler B, Walker UA, Tyndall A, et al. (2011) Th17 cells, not IL-17+ γδ T cells, drive arthritic bone destruction in mice and humans. J Immunol 186: 2602-2612. doi:10.4049/jimmunol.1003370. PubMed: 21217016.
32. Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, et al. (2010) LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 62: 929-939. doi:10.1002/art.27334. PubMed: 20131262.
33. Aslakson CJ, Miller FR, (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52: 1399-1405. PubMed: 1540948.
34. Suzuki C, Jacobsson H, Hatschek T, Torkzad MR, Bodén K, et al. (2008) Radiologic measurements of tumor response to treatment: practical approaches and limitations. RadioGraphics 28: 329-344. doi:10.1148/rg.282075068. PubMed: 18349443.
35. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, et al. (1999) A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 17: 163-170. doi:10.1023/A:1006689719505. PubMed: 10411109.
36. Gao Y, Grassi F, Ryan MR, Terauchi M, Page K, et al. (2007) IFN-gamma stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest 117: 122-132. doi:10.1172/JCI30074. PubMed: 17173138.
37. Zaiss MM, Axmann R, Zwerina J, Polzer K, Gückel E, et al. (2007) Treg cells suppress osteoclast formation: a new link between the immune system and bone. Arthritis Rheum 56: 4104-4112. doi:10.1002/art.23138. PubMed: 18050211.
38. Hirsch HM, Iversen I, (1961) Accelerated development of spontaneous mammary tumors in mice pretreated with mammary tumor tissue and adjuvant. Cancer Res 21: 752-760. PubMed: 13714571.
39. Martinez C, (1964) EFFECT OF EARLY THYMECTOMY ON DEVELOPMENT OF MAMMARY TUMOURS IN MICE. Nature 203: 1188. doi:10.1038/2031188a0. PubMed: 14213682.
40. Yunis EJ, Martinez C, Smith J, Stutman O, Good RA, (1969) Spontaneous mammary adenocarcinoma in mice: influence of thymectomy and reconstitution with thymus grafts or spleen cells. Cancer Res 29: 174-178. PubMed: 4303909.
41. Roy LD, Ghosh S, Pathangey LB, Tinder TL, Gruber HE, et al. (2011) Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer. BMC Cancer 11: 365-384. doi:10.1186/1471-2407-11-365. PubMed: 21859454.
42. Jovanovic I, Radosavljevic G, Mitrovic M, Juranic VL, McKenzie AN, et al. (2011) ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma. Eur J Immunol 41: 1902-1912. doi:10.1002/eji.201141417. PubMed: 21484786.
43. Kim N, Odgren PR, Kim DK, Marks SC Jr, Choi Y, (2000) Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci U S A 97: 10905-10910. doi:10.1073/pnas.200294797. PubMed: 10984520.
44. Ernst CW, Lee JE, Nakanishi T, Karimbux NY, Rezende TM, et al. (2009) Diminished forkhead box P3/CD25 double-positive T regulatory cells are associated with the increased nuclear factor-kB ligand (RANKL+) T cells in bone resorption lesion of periodontal disease. Clin Exp Immunol 148: 271-280.
45. Tan W, Zhang W, Strasner A, Grivennikov S, Cheng JQ, et al. (2011) Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 470: 548-553. doi:10.1038/nature09707. PubMed: 21326202.
46. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, et al. (2010) Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468: 98-102. doi:10.1038/nature09387. PubMed: 20881962.
47. Palafox M, Ferrer I, Pellegrini P, Vila S, Hernandez-Ortega S, et al. (2012) RANK Induces Epithelial-Mesenchymal Transition and Stemness in Human Mammary Epithelial Cells and Promotes Tumorigenesis and Metastasis. Cancer Res 72: 2879-2888. doi:10.1158/0008-5472.CAN-12-0044. PubMed: 22496457.